Sign In
Buy PRNB
$100.05
+0 (+0%)
At Close: May 27, 2022
Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
10:05am, Friday, 12'th Jun 2020
A total of 47 heavily pre-treated patients (median of six prior therapies) with immune thrombocytopenia (ITP) have been enrolled with a median follow-up of 18 weeks. Data from this trial are being pr
Principia Biopharma (NASDAQ:PRNB) Cut to Hold at BidaskClub
07:04am, Wednesday, 10'th Jun 2020
Principia Biopharma (NASDAQ:PRNB) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, BidAskClub reports. Other equities re
The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage
05:43pm, Sunday, 07'th Jun 2020
The biotech space saw a flurry of activity last week, with coronavirus-related news, conference presentations and IPOs.Negative clinical readouts led to some strong selling in stocks such as Iterum T
The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage
12:00am, Sunday, 07'th Jun 2020
The biotech space saw a flurry of activity last week, with coronavirus-related news, conference presentations and IPOs.
Negative clinical readouts led to some strong selling in...
Principia Biopharma to Hold Virtual Analyst Event to Discuss BTK Inhibition: Beyond B Cells and Antibodies
08:01pm, Wednesday, 03'rd Jun 2020
Principia is a late-stage biopharmaceutical company dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune-mediated diseases. Through Principia’s
SOUTH SAN FRANCISCO, Calif., May 26, 2020 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for.
Principia Biopharma Reports First Quarter 2020 Financial Results
08:05pm, Wednesday, 06'th May 2020
SOUTH SAN FRANCISCO, Calif., May 06, 2020 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for.
Principia Biopharma to Present at the 2020 Bank of America Health Care Conference
08:05pm, Tuesday, 05'th May 2020
Principia is a late-stage biopharmaceutical company dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune-mediated diseases. Through Principia’s
Recent Analysts' Ratings Changes for Principia Biopharma (PRNB)
06:30am, Thursday, 30'th Apr 2020
Principia Biopharma (NASDAQ: PRNB) has recently received a number of price target changes and ratings updates: 4/28/2020 – Principia Biopharma was downgraded by analysts at Zacks Investment Research
Earnings Preview: Principia Biopharma Inc. (PRNB) Q1 Earnings Expected to Decline
04:33pm, Tuesday, 28'th Apr 2020
Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Principia Biopharma Inc. (PRNB) Q1 Earnings Expected to Decline
04:33pm, Tuesday, 28'th Apr 2020
Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stifel Nicolaus Remains a Buy on Principia Biopharma (PRNB)
08:07am, Monday, 27'th Apr 2020
In a report issued on April 23, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Principia Biopharma (PRNB). The company's shares closed last
Stifel Nicolaus Remains a Buy on Principia Biopharma (PRNB)
08:07am, Monday, 27'th Apr 2020
In a report issued on April 23, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Principia Biopharma (PRNB
Principia Biopharma (NASDAQ:PRNB) Stock Rating Upgraded by Zacks Investment Research
08:30am, Saturday, 25'th Apr 2020
Zacks Investment Research upgraded shares of Principia Biopharma (NASDAQ:PRNB) from a hold rating to a buy rating in a report issued on Tuesday, Zacks.com reports. Zacks Investment Research currently
Bank of America Corp DE Raises Stock Position in Principia Biopharma Inc (NASDAQ:PRNB)
09:06am, Friday, 24'th Apr 2020
Bank of America Corp DE grew its holdings in Principia Biopharma Inc (NASDAQ:PRNB) by 92.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 20,123 shares of the co
